RxDoctor Payments Data

Robert Johnson

Acute Care · Gainesville, GANPI 1750060273

Payments from drug & device makers

$2,228in general payments, 2019–2025

Across 103 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$672
  • AstraZeneca$402
  • Sanofi$175
  • Insmed, Inc.$163
  • Verona Pharma, Inc.$162
  • Takeda Pharmaceuticals U.S.A., Inc.$143
  • plus $510 from 8 others

What the payments were for

  • Food & beverage$2,21199%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,228 in reported general payments places this provider in the 85th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Medicare billing

Part B allowed, 2024
$43,161
Medicare patients
306
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter241$171,309
Breztri AerosphereBudesonide/Glycopyr/Formoterol54$37,544
Breo ElliptaFluticasone/Vilanterol42$18,862
Incruse ElliptaUmeclidinium Bromide41$16,201
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$13,566
Spiriva RespimatTiotropium Bromide20$12,730
Fluticasone-SalmeterolFluticasone Propion/Salmeterol98$12,122
Albuterol Sulfate HfaAlbuterol Sulfate355$9,787
Combivent RespimatIpratropium/Albuterol Sulfate13$6,242
Wixela InhubFluticasone Propion/Salmeterol38$5,928
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,540
Arnuity ElliptaFluticasone Furoate13$3,769
SymbicortBudesonide/Formoterol Fumarate15$3,416
Ventolin HfaAlbuterol Sulfate27$1,520
Ipratropium Bromide37$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$672$215,681349 claims
AstraZenecaBreztri Aerosphere, Symbicort$402$40,96169 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$135$32,53858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 679 acute care providers in Georgia.

Other acute care in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →